Streetbeat News

AUPH

Aurinia Pharmaceuticals Inc.

https://www.auriniapharma.com

Industry

Biotechnology

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

Open

8.36

Mkt cap

1.2B

Volume

1.4M

High

8.39

P/E Ratio

-54.13

52-wk high

10.05

Low

8.07

Div yield

N/A

52-wk low

4.71

Aurinia Pharmaceuticals has adjusted its 2024 net product revenue range from $200M-$220M to $210M-$220M, indicating a more optimistic outlook.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:03 am

Aurinia Pharmaceuticals (NASDAQ:AUPH) reported Q2 2024 GAAP EPS of $0.01, meeting analyst expectations. The company also reported sales of $57.2 million, beating the $55.055 million estimate by 3.90%, and marking a 37.85% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2024 | 10:02 am

ILJIN SNT Co., Ltd has announced its intention to vote against Aurinia Pharmaceuticals's revised equity incentive plan proposal.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2024 | 3:48 pm

Aurinia Pharmaceuticals announced an upcoming oral presentation at the European Alliance of Associations for Rheumatology 2024 in Vienna, Austria, from June 12-15. The presentation will cover the safety and efficacy profile of Lupkynis for people with lupus nephritis.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 10:02 am

Aurinia Pharmaceuticals issued a letter to shareholders addressing concerns about shareholder Lucien Selce's credibility. The company recommends shareholders review a report from proxy advisor Glass Lewis, which supports the re-election of all nine incumbent directors.

Portfolio Pulse from Benzinga Newsdesk

June 04, 2024 | 9:35 pm

Aurinia Pharmaceuticals shareholder urges fellow shareholders to withhold support for CEO Peter Greenleaf, suggesting that his removal would lead to a superior board and strategy for the company.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:33 pm

A recent analysis presented at the National Kidney Foundation's Spring Clinical Meeting 2024 has shown that LUPKYNIS is a cost-effective treatment for Lupus Nephritis. This finding could have significant implications for its manufacturer, Aurinia Pharmaceuticals Inc. (AUPH), in terms of market positioning and potential sales growth.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 10:09 am

Aurinia Pharmaceuticals presented two studies at the Annual Congress of Clinical Rheumatology, reinforcing the safety and effectiveness of LUPKYNIS (voclosporin) in treating adult patients with active lupus nephritis (LN) in combination with MMF and steroids, as demonstrated in the AURORA Clinical Program.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 10:13 am

Lucien Selce, owning 2.2% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), criticizes the company's board and strategy, particularly in market penetration of Lupkynis and board composition. Selce suggests reducing the board size, linking management compensation to revenue goals, and developing strategic partnerships. He highlights the board's failures, including poor communication, irrelevant skill sets of directors, and questionable decisions by CEO Peter Greenleaf. Selce calls for immediate board restructuring before the Annual General Meeting to enhance shareholder value.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 1:18 pm

Aurinia Pharmaceuticals has reaffirmed its net product revenue guidance for the year 2024, projecting revenues to be in the range of $200 million to $220 million. This announcement is a significant indicator of the company's financial health and future prospects.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 10:04 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.